Suscribirse

Post-donation information and haemovigilance reporting for COVID-19 in Greece: Information supporting the absence of SARS-CoV-2 possible transmission through blood components - 31/01/21

Doi : 10.1016/j.tracli.2020.10.007 
C. Politis a, , M. Papadaki b, L. Politi c, G. Kourti d, C. Richardson e, M. Asariotou a, A. Tsakris c, A. Mentis f
a Coordinating Centre for Haemovigilance and Surveillance of Transfusion, Hellenic National Public Health Organization,, Athens, Greece 
b Blood transfusion service, Sotiria thoracic diseases hospital of Athens, Athens, Greece 
c Laboratory of microbiology, medical school, National and Kapodistrian University of Athens, Athens, Greece 
d Haematology department, Sotiria thoracic diseases hospital of Athens, Athens, Greece 
e Panteion university of social and political sciences, Athens, Greece 
f Public health laboratories, Hellenic Pasteur Institute, Athens, Greece 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

Although the SARS-CoV-2 virus is transmitted mainly through the respiratory tract, possible transmission by transfusion from asymptomatic carriers should be explored. As yet there are no reports of transfusion transmission of COVID-19. Haemovigilance findings within a three-month surveillance period during the new coronavirus pandemic are presented.

Materials and methods

Due to great demand and shortage, blood sessions in outpatient facilities were organized during the high prevalence period of COVID-19, alongside a national plan to monitor the evolving public health situation by random molecular screening of high-risk groups of the population. Haemovigilance protocols were implemented as well as surveillance for any COVID-19 case reported post-transfusion. A 14-day quarantine and follow-up molecular and antibody testing of any COVID-19 positive case was obligatory.

Results

Post-donation, post-transfusion information and molecular testing of swab samples collected from three asymptomatic donors at risk for COVID-19, revealed the case of an immunosupressed patient who had been transfused with whole blood derived platelets from a donor subsequently diagnosed with COVID-19. The recipient exhibited no symptoms of the disease. Molecular and antibody testing results were negative.

Conclusion

Haemovigilance provided information supporting the absence of transfusion transmission of COVID-19, thus strengthening the hypothesis that, even if it cannot yet be definitively ruled out, COVID-19 is not transmitted through blood transfusion. As of early June 2020, a perfect test does not exist, therefore haemovigilance along with the implementation of strict proactive measures is crucial to identify eluding asymptomatic individuals and ensure blood safety during the pandemic.

El texto completo de este artículo está disponible en PDF.

Keywords : SARS-CoV-2, Transfusion transmission, Haemovigilance


Esquema


© 2020  Société française de transfusion sanguine (SFTS). Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 28 - N° 1

P. 55-59 - février 2021 Regresar al número
Artículo precedente Artículo precedente
  • Serum pooling for rapid expansion of anti-SARS-CoV-2 antibody testing capacity
  • J.W.L. Allen, H. Verkerke, J. Owens, B. Saeedi, D. Boyer, S. Shin, J.D. Roback, A.S. Neish, S.R. Stowell
| Artículo siguiente Artículo siguiente
  • The impact of COVID-19 on transfusion-dependent thalassemia patients of Karachi, Pakistan: A single-center experience
  • S. Arshad Ali, D. Azim, H.M. Hassan, A. Iqbal, N. Ahmed, S. Kumar, S. Nasim

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.